Tirzepatide vs. Semaglutide for obesity and metabolic syndrome in adults
Official title: Comparative Adipose Tissue and Cardiometabolic System Remodeling by Tirzepatide and Semaglutide: an AI-integrated Multimodal Metabolomics and Translational Mechanistic Study
Run by Tri-Service General Hospital (TSGH) · NCT07589322 · Data updated 2026-11-12
This study tests whether tirzepatide leads to different fat loss and heart-metabolism changes than semaglutide in adults with obesity and metabolic syndrome.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years to 65 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Tri-Service General Hospital (TSGH) Academic / other |
| Locations | 1 site (Taipei) |
| Status | Recruiting |
| Started | March 31, 2026 |
| Main results expected | September 30, 2028 |
| Study ends | September 30, 2029 |
| Registry record updated | May 15, 2026 |
| Trial ID | NCT07589322 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 20–65 with BMI ≥27 kg/m² and metabolic syndrome.
✕Probably not a fit
Patients who do not respond to incretin therapy or have contraindications to MRI/DXA may see limited benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a single-center, randomized, open-label trial comparing tirzepatide to semaglutide in adults with obesity and metabolic syndrome over 12 months. Participants receive lifestyle counseling and undergo deep phenotyping, including body composition by DXA, liver fat by MRI, skinfolds, grip strength, fasting biomarkers, and AI-enhanced ECGs, with centralized banking of bio samples for multi-omic analyses. The study aims to characterize how each drug affects adipose tissue remodeling and cardiometabolic parameters over time. Randomization is 1:1 and stratified by sex and baseline BMI, with visits at baseline, 3, 6, and 12 months and phenotyping at baseline, 6, and 12 months.
Why it matters
Potential benefit: If successful, the trial could clarify which incretin therapy yields more favorable fat distribution and metabolic improvements.
How similar studies have gone: Previous studies in incretin therapies show meaningful metabolic effects, but direct head-to-head mechanistic comparisons like this are less common.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 20-65 years. * BMI ≥27 kg/m² with metabolic syndrome (ATP III or IDF criteria). * Stable background medications (antihypertensives, statins, etc.) for ≥3 months. * Able and willing to provide informed consent and comply with study procedures. Exclusion Criteria: * History of diabetes; history of pancreatitis; personal/family history of medullary thyroid carcinoma or MEN2. * eGFR \<30 mL/min/1.73 m², decompensated liver disease, NYHA class III-IV heart failure. * Recent (\<3 months) acute coronary syndrome, stroke, or coronary revascularization. * Current use of GLP 1RA, tirzepatide, or other incretin based therapies within 3 months. * Contraindications to MRI or DXA (e.g., metal implants incompatible with MRI, pregnancy).
Where it's running
-
Tri-Service General Hospital
Taipei, Taiwan Recruiting
Study contacts
- Study coordinator: Feng-Chih Kuo, M.D., Ph.D.
- Email: shoummie@hotmail.com
- Phone: 886-2-87923311
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Fulvic acid supplements for metabolic syndrome
This study tests whether 50 mg or 100 mg of fulvic acid daily for 12 weeks can help people with metabolic syndrome or prediabetes.
-
Asprosin and miRNA Profiles in Young Women with Metabolic Syndrome
This study tests whether certain blood biomarkers, including asprosin and six microRNAs, differ between young women with metabolic syndrome and healthy peers.
-
Using Multimodal Ultrasound to Check Muscle Mass in Metabolic Disease Patients
This study tests whether a multimodal ultrasound approach can accurately measure muscle mass in people with metabolic syndrome, obesity, sarcopenia, or type 2 diabetes.
-
Low-Calorie Diet in adolescents with Familial Mediterranean Fever and metabolic syndrome
A group of adolescents with both FMF and metabolic syndrome will try a low-calorie diet for 3 months to see if it helps manage metabolic symptoms.
-
Exercise for Metabolic Syndrome and Fatty Liver in Adolescent Girls with Celiac Disease
This study tests whether a 3-month walking program helps improve metabolic syndrome and fatty liver in adolescent females with celiac disease.
-
Longevity Metrics AI/ML Development Study
Researchers are testing AI models that score health screening tests and predict outcomes like life expectancy for adults, using ongoing follow-up data.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.